Bagsværd, Denmark, 17 January 2025 – Novo Nordisk today announced headline results from STEP UP, a phase 3b trial in the global STEP programme. STEP UP is a 72-week efficacy and safety trial investigating subcutaneous semaglutide 7.2 mg compared to semaglutide 2.4 mg and placebo,...Read more
ADDIS ABABA, Ethiopia and KINSHASA, Democratic Republic of the Congo and WASHINGTON and PARIS, Jan. 16, 2025 (GLOBE NEWSWIRE) -- Africa CDC’s support for the MOSA, a pan-African randomized platform adaptive trial for the MpOx Study, adding to the initial EU funding, has enabled the...Read more
Company on track to report topline data in first half of 2025 Positive preliminary data from all five single ascending dose (SAD) cohorts ranging from 15mg to 450mg support safety and tolerability of PALI-2108 Continued progress toward Phase 1b/2a of PALI-2108 trial for the...Read more
First approval in the US for AstraZeneca and Daiichi Sankyo’s DATROWAY based on TROPION-Breast01 results showing 37% reduction in the risk of disease progression or death vs. chemotherapy DATROWAY is the eighth new medicine of the 20 AstraZeneca has set out to deliver by 2030 WILMINGTON, Del....Read more
Based on ECHO Phase III trial results which showed more than 16 months of progression-free survival improvement vs. chemoimmunotherapy alone First and only BTK inhibitor approved for the 1st-line treatment of MCL in the US WILMINGTON, Del. / Jan 17, 2025 / Business Wire / AstraZeneca’s...Read more
Pivotal Study Demonstrated the Combination More Than Doubled Progression-Free Survival Compared to Investigated SOC THOUSAND OAKS, Calif., Jan. 17, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved LUMAKRAS® (sotorasib) in...Read more
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. The company's lead cell therapy asset is NXC-201 in multiple myeloma...
CLICK TO LEARN MORE| Company | Change | Last Trade |
|---|---|---|
| Madrigal Pharmaceuticals | 20.85 7.64 | $293.64 |
| Agilent Technologies | 11.26 8.27 | $147.36 |
| Intuitive Surgical | 8.56 1.47 | $592.64 |
| Humana | 6.83 2.48 | $282.63 |
| Semler Scientific | 6.44 11.06 | $64.68 |
| Blueprint Medicines | 6.10 5.87 | $110.05 |
| Vertex Pharmaceuticals | 5.04 1.21 | $422.00 |
| MoonLake Immunotherapeutics | 4.29 10.34 | $45.76 |
| Inspire Medical Systems | 3.85 2.21 | $177.68 |
| Molina Healthcare | 3.61 1.28 | $286.21 |
| Krystal Biotech | 3.58 2.47 | $148.39 |
| Accolade | 3.45 100.29 | $6.89 |
| Sonendo | 3.27 1,421.74 | $3.50 |
| Belite Bio | 3.17 5.98 | $56.21 |
| Cigna | 3.02 1.07 | $283.99 |
| Insulet | 2.95 1.08 | $275.81 |
| Rigel Pharmaceuticals | 2.78 16.02 | $20.13 |
| Vericel | 2.72 4.83 | $59.07 |
| Company | Volume | Last Trade |
|---|---|---|
| AEON Biopharma | 140,369,555 | $0.14 |
| Electromedical Technologies | 136,407,349 | $0.00 |
| Aclarion | 84,806,159 | $0.04 |
| Tonix Pharmaceuticals | 37,918,406 | $0.24 |
| Aditxt | 36,489,487 | $0.13 |
| Eyenovia | 33,535,056 | $0.06 |
| Pfizer | 31,348,496 | $26.30 |
| Walgreens Boots Alliance | 28,352,948 | $12.45 |
| BioLineRx | 25,604,071 | $0.10 |
| Channel Therapeutics | 24,846,854 | $1.91 |
| Quantum-Si | 22,450,948 | $2.25 |
| Novo Nordisk | 20,089,011 | $78.77 |
| Senseonics | 19,034,579 | $0.85 |
| Merck | 14,885,567 | $97.92 |
| CNS Pharmaceuticals | 14,815,455 | $0.10 |
| iSpecimen | 14,680,787 | $2.45 |
| Conduit Pharmaceuticals | 13,010,547 | $0.07 |
| CVS Health | 11,879,508 | $52.62 |
| ImmunityBio | 11,639,190 | $2.94 |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including a small-molecule GLP-1 receptor...
CLICK TO LEARN MORE
Viking Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel first-in-class or best-in-class therapies for the treatment of metabolic and endocrine disorders, with three compounds currently in clinical trials. Viking’s research and development activities leverage...
CLICK TO LEARN MORE
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
